{"organizations": [], "uuid": "0b72fc1338d650e2d65f4eb5f6b352f1c60e1749", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/05/08/the-associated-press-aimmune-therapeutics-1q-earnings-snapshot.html", "country": "US", "domain_rank": 767, "title": "Aimmune Therapeutics: 1Q Earnings Snapshot", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-09T01:08:00.000+03:00", "replies_count": 0, "uuid": "0b72fc1338d650e2d65f4eb5f6b352f1c60e1749"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/05/08/the-associated-press-aimmune-therapeutics-1q-earnings-snapshot.html", "ord_in_thread": 0, "title": "Aimmune Therapeutics: 1Q Earnings Snapshot", "locations": [], "entities": {"persons": [], "locations": [{"name": "calif.", "sentiment": "none"}, {"name": "brisbane", "sentiment": "none"}, {"name": "brisbane", "sentiment": "none"}], "organizations": [{"name": "aimt", "sentiment": "negative"}, {"name": "aimmune therapeutics inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "aimmune therapeutics", "sentiment": "none"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BRISBANE, Calif. (AP) _ Aimmune Therapeutics Inc. (AIMT) on Tuesday reported a loss of $49.5 million in its first quarter.\nOn a per-share basis, the Brisbane, California-based company said it had a loss of 92 cents.\nThe results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 66 cents per share.\nAimmune Therapeutics shares have dropped 18 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $30.99, a climb of 61 percent in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on AIMT at https://www.zacks.com/ap/AIMT", "external_links": ["https://www.zacks.com/ap/AIMT", "http://automatedinsights.com/ap"], "published": "2018-05-09T01:08:00.000+03:00", "crawled": "2018-05-09T00:35:07.000+03:00", "highlightTitle": ""}